Eris Lifesciences Limited — Board Meeting, 05-08-2025: Outcome of Board Meeting

Eris Lifesciences' Board has approved its consolidated financial results for the quarter ended June 30, 2025. The company delivered strong performance, with Revenue from Operations climbing to ₹773.00 Cr from ₹719.72 Cr in the prior year. Net Profit saw a substantial rise, reaching ₹117.99 Cr compared to ₹83.31 Cr previously. Basic Earnings Per Share (EPS) also improved to ₹8.66 from ₹6.11. Additionally, 34,756 shares were allotted under the employee stock option scheme.